The rise of Viagra initially sparked a surge for major pharmaceutical companies, but recent shifts present a uncertain picture for shareholders. Off-patent versions are reducing revenue, and persistent patent https://mathenqxp377483.blogars.com/39675242/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-investment